Merck Drug Patent Portfolio
Merck owns 3 orange book drugs protected by 26 US patents Given below is the list of Merck's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994329 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US6225294 | Method for inhibiting bone resorption | 17 Jan, 2019 | Expired |
| US5994329 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6015801 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6225294 | Method for inhibiting bone resorption | 17 Jul, 2018 | Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases | 06 Nov, 2017 | Expired |
| US5952300 | Antifungal compositions | 28 Sep, 2017 | Expired |
| US6136783 | Antifungal compositions | 28 Sep, 2017 | Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases | 06 May, 2017 | Expired |
| US5952300 | Antifungal compositions | 28 Mar, 2017 | Expired |
| US6136783 | Antifungal compositions | 28 Mar, 2017 | Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors | 18 Nov, 2015 | Expired |
| US5514650 | Aza cyclohexapeptide compounds | 26 Jul, 2015 | Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors | 18 May, 2015 | Expired |
| US5514650 | Aza cyclohexapeptide compounds | 26 Jan, 2015 | Expired |
| US5462932 | Oral liquid alendronate formulations | 17 Nov, 2014 | Expired |
| US5462932 | Oral liquid alendronate formulations | 17 May, 2014 | Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors | 24 Dec, 2013 | Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor | 24 Dec, 2013 | Expired |
| US5378804 | Aza cyclohexapeptide compounds | 16 Sep, 2013 | Expired |
| US5792746 | Aza cyclohexapeptide compounds | 16 Sep, 2013 | Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors | 24 Jun, 2013 | Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor | 24 Jun, 2013 | Expired |
| US5378804 | Aza cyclohexapeptide compounds | 16 Mar, 2013 | Expired |
| US5792746 | Aza cyclohexapeptide compounds | 16 Mar, 2013 | Expired |
Merck's Family Patents
Clinical Trials
Recent Clinical Trials by Merck:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study of the Efficacy and Safety of Vibegron (MK-4618) in Participants With Overactive Bladder (OAB) (MK-4618-008) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Jan, 2019)
| PHASE2 |
| A Study of the Pharmacokinetics and Pharmacodynamics of Vibegron (MK-4618) in Women With Overactive Bladder (MK-4618-004) | Merck Sharp & Dohme LLC | NA |
TERMINATED
(Dec, 2018)
| PHASE1 |
| A Single Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Participants With Renal Insufficiency (MK-4618-014) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Dec, 2018)
| PHASE1 |
| A Single-Dose Study of the Pharmacokinetics of Vibegron (MK-4618) in Adults With Hepatic Insufficiency (MK-4618-013) | Merck Sharp & Dohme LLC | NA |
COMPLETED
(Dec, 2018)
| PHASE1 |
Merck Drug List
Given below is the complete list of Merck's drugs and the patents protecting them.
1. Cancidas
Cancidas is protected by 10 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5952300
(Pediatric)
| Antifungal compositions |
28 Sep, 2017
(8 years ago)
| Expired |
| US6136783
(Pediatric)
| Antifungal compositions |
28 Sep, 2017
(8 years ago)
| Expired |
| US5952300 | Antifungal compositions |
28 Mar, 2017
(8 years ago)
| Expired |
| US6136783 | Antifungal compositions |
28 Mar, 2017
(8 years ago)
| Expired |
| US5514650
(Pediatric)
| Aza cyclohexapeptide compounds |
26 Jul, 2015
(10 years ago)
| Expired |
| US5514650 | Aza cyclohexapeptide compounds |
26 Jan, 2015
(10 years ago)
| Expired |
| US5378804
(Pediatric)
| Aza cyclohexapeptide compounds |
16 Sep, 2013
(12 years ago)
| Expired |
| US5792746
(Pediatric)
| Aza cyclohexapeptide compounds |
16 Sep, 2013
(12 years ago)
| Expired |
| US5378804 | Aza cyclohexapeptide compounds |
16 Mar, 2013
(12 years ago)
| Expired |
| US5792746 | Aza cyclohexapeptide compounds |
16 Mar, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Cancidas's drug page
2. Fosamax
Fosamax is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5994329
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US6015801
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US6225294
(Pediatric)
| Method for inhibiting bone resorption |
17 Jan, 2019
(6 years ago)
| Expired |
| US5994329 | Method for inhibiting bone resorption |
17 Jul, 2018
(7 years ago)
| Expired |
| US6015801 | Method for inhibiting bone resorption |
17 Jul, 2018
(7 years ago)
| Expired |
| US6225294 | Method for inhibiting bone resorption |
17 Jul, 2018
(7 years ago)
| Expired |
| US5462932
(Pediatric)
| Oral liquid alendronate formulations |
17 Nov, 2014
(10 years ago)
| Expired |
| US5462932 | Oral liquid alendronate formulations |
17 May, 2014
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Fosamax's drug page
3. Vioxx
Vioxx is protected by 8 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6063811
(Pediatric)
| Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
06 Nov, 2017
(7 years ago)
| Expired |
| US6063811 | Compositions for a once day treatment of cyclooxygenase-2 mediated diseases |
06 May, 2017
(8 years ago)
| Expired |
| US5691374
(Pediatric)
| Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
18 Nov, 2015
(9 years ago)
| Expired |
| US5691374 | Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors |
18 May, 2015
(10 years ago)
| Expired |
| US5474995
(Pediatric)
| Phenyl heterocycles as cox-2 inhibitors |
24 Dec, 2013
(11 years ago)
| Expired |
| US6239173
(Pediatric)
| 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
24 Dec, 2013
(11 years ago)
| Expired |
| US5474995 | Phenyl heterocycles as cox-2 inhibitors |
24 Jun, 2013
(12 years ago)
| Expired |
| US6239173 | 3-phenyl-4-(4(methylsulfonyl)phenyl)-2-(5H)-furanone as a cox-2 inhibitor |
24 Jun, 2013
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Vioxx's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List